Dermorphin vs Somatropin (HGH)
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinGrowth Hormone PeptidesAnti-Aging & Longevity
Somatropin (HGH)- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Somatropin is recombinant human growth hormone (rhGH), identical in structure to the 191-amino acid pituitary-derived growth hormone. It is FDA-approved for growth hormone deficiency, short stature, and wasting conditions. Off-label, it is widely explored for body composition, anti-aging, and performance enhancement, though significant risks accompany unsupervised use.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- 2-3 hours (subcutaneous); 20-30 minutes (intravenous)
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- Subcutaneous, Intramuscular (less common)
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 0.15-0.3 mg/day (adults); titrated to IGF-1 levels
- Frequency
- Not established
- Once daily
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Increases lean muscle mass and reduces body fat (particularly visceral)
- Restores growth hormone deficiency (FDA-approved)
- Improves bone mineral density
- Enhances exercise capacity and recovery
- Supports skin thickness and collagen synthesis
- Improves lipid profile in GHD patients
- Explored for anti-aging and cellular regeneration
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Fluid retention and edema (common, dose-dependent)
- Carpal tunnel syndrome
- Joint and muscle pain
- Insulin resistance and elevated blood glucose
- +3 more
- Stacks With
- —
- —